| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 218.2 | 245.3 | 203.2 |
| Other income | 0.3 | 0.2 | 2.6 |
| Total income | 218.5 | 245.4 | 205.8 |
| Profit before exceptional items & tax | 17.5 | 35.2 | 44.8 |
| Profit before tax | 17.5 | 35.2 | 44.8 |
| Net profit | 14.1 | 27.5 | 29.9 |
| Operating margin | 8.0% | 14.3% | 21.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -52.80% |
|---|---|
| Net profit, quarter on quarter | -48.70% |
| Revenue, year on year | +7.40% |
| Operating profit, year on year | -59.20% |
| Operating profit, quarter on quarter | -50.90% |
BSE results filing, NSE: SYMBIOTEC. Figures extracted from the filing.
Symbiotec Pharmalab Ltd: key numbers
- Share price
- ₹1,003.35
- Market cap
- ₹6,447 Cr
- Revenue (annual)
- ₹869.1 Cr
- Net profit (annual)
- ₹109.9 Cr
- Promoter holding
- 33.28%
- FII holding
- 21.08%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Symbiotec Pharmalab Ltd
All →Symbiotec Pharmalab Earnings Call Transcript: Key Takeaways
Symbiotec reported Q1 FY27 Revenue of ₹218 Cr, but underlying PAT remains soft due to heavy pre-operative expense drags from unmonetized new business segments.
- Call
- Guides 20% growth
Symbiotec Pharmalab Results Update
Symbiotec Pharmalab released its Q1FY27 investor update. The company reported consolidated revenue of Rs. 218.2 Crore and PAT of Rs. 14.1 Crore for the period.
Symbiotec Pharmalab Investor Presentation: Key Takeaways
Symbiotec Pharmalab Q1FY27 results show steady 7% revenue growth in core API business, offset by high opex/depreciation from significant new capex in Injectables and CDMO services.
Symbiotec Pharmalab Board Meeting Date
Symbiotec Pharmalab Ltd scheduled a board meeting for September 21, 2026, to consider financial results for the quarter ended June 30, 2026.
Symbiotec Pharmalab Share Pledge
Symbiotec Pharmalab promoters pledged 34.93 lakh shares (~5.44%) to debenture trustee Beacon Trusteeship. This Securitisation encumbrance secures the company's debenture issue.
Symbiotec Pharmalab Capital Structure Change
Mirae Asset Mutual Fund acquired 34,97,420 shares of Symbiotec Pharmalab Ltd. This open market purchase increased their stake from 0.78% to 6.22%.